XML 61 R49.htm IDEA: XBRL DOCUMENT v3.23.3
Deferred Royalty Obligation related to the Sale of Future Royalties Additional Information (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Jun. 30, 2023
Sep. 30, 2023
Sep. 30, 2023
Deferred Royalty Obligation [Line Items]      
Non-cash interest expense on deferred royalty obligation   $ 5,900 $ 6,378
Percentage of interest rate amortize liability   17.00% 17.00%
Blackstone Life Sciences      
Deferred Royalty Obligation [Line Items]      
Upfront payment received $ 140,000    
Blackstone Life Sciences | Maximum      
Deferred Royalty Obligation [Line Items]      
Milestone payment receivable 250,000    
2015 License Agreement | Blackstone Life Sciences      
Deferred Royalty Obligation [Line Items]      
Transaction costs incurred 3,800    
2015 License Agreement | Blackstone Life Sciences | Royalty      
Deferred Royalty Obligation [Line Items]      
Upfront payment received $ 140,000    
Revenue interest percentage 4.00%